The xenon-mediated antagonism against the NMDA receptor is non-selective for receptors containing either NR2A or NR2B subunits in the mouse amygdala

European Journal of Pharmacology

Volumn 619, Issue 1-3, 2009, Pages 33-37

  Haseneder, Rainer ^a   Kratzer, Stephan ^a   Kochs, Eberhard ^a   Höfelmann, Daniela ^a   Auberson, Yves ^c   Eder, Matthias ^b   Rammes, Gerhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anaesthetic; NMDA (N methyl d aspartate) receptor; NR2A (NMDA receptor subunit type 2A); NR2B (NMDA receptor subunit type 2B); Subunit; Xenon

Indexed keywords

GLUTAMIC ACID; METHYLPHOSPHONIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; XENON;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN SLICE; CONTROLLED STUDY; DRUG ACTIVITY; MALE; MOUSE; NONHUMAN; PATCH CLAMP; PHOTOLYSIS; PRIORITY JOURNAL; RECEPTOR BLOCKING;

AMYGDALA; ANESTHETICS, INHALATION; ANIMALS; ELECTRIC CONDUCTIVITY; MALE; MICE; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTRATE SPECIFICITY; TIME FACTORS; XENON;

EID: 69749104675     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.011     Document Type: Article

References (44)

1. Akazawa C., Shigemoto R., Bessho Y., Nakanishi S., and Mizuno N. Differential expression of five N-methyl-d-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J. Comp. Neurol. 347 (1994) 150-160
2. Auberson Y.P., Allgeier H., Bischoff S., Lingenhoehl K., Moretti R., and Schmutz M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg. Med. Chem. Lett. 12 (2002) 1099-1102
3. Barth A.L., and Malenka R.C. NMDAR EPSC kinetics do not regulate the critical period for LTP at thalamocortical synapses. Nat. Neurosci. 4 (2001) 235-236
4. de Sousa S.L., Dickinson R., Lieb W.R., and Franks N.P. Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology 92 (2000) 1055-1066
5. Dickinson R., Peterson B.K., Banks P., Simillis C., Martin J.C., Valenzuela C.A., Maze M., and Franks N.P. Competitive inhibition at the glycine site of the N-methyl-d-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology 107 (2007) 756-767
6. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51 (1999) 7-61
7. Dingley J., Tooley J., Porter H., and Thoresen M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 37 (2006) 501-506
8. Dodt H.U., Eder M., Schierloh A., and Zieglgansberger W. Infrared-guided laser stimulation of neurons in brain slices. Sci. STKE. 2002 (2002) L2
9. Feng B., Tse H.W., Skifter D.A., Morley R., Jane D.E., and Monaghan D.T. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2, 3-dicarboxylic acid. Br. J. Pharmacol. 141 (2004) 508-516
10. Fischer G., Mutel V., Trube G., Malherbe P., Kew J.N., Mohacsi E., Heitz M.P., and Kemp J.A. Ro 25-6981, a highly potent and selective blocker of N-methyl-d-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. 283 (1997) 1285-1292
11. Flint A.C., Maisch U.S., Weishaupt J.H., Kriegstein A.R., and Monyer H. NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J. Neurosci. 17 (1997) 2469-2476
12. Franks N.P., Dickinson R., de Sousa S.L., Hall A.C., and Lieb W.R. How does xenon produce anaesthesia?. Nature 396 (1998) 324
13. Frizelle P.A., Chen P.E., and Wyllie D.J. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2, 3-dioxo-1, 2, 3, 4-tetrahydroquino xalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-d-aspartate receptors: implications for studies of synaptic transmission. Mol. Pharmacol. 70 (2006) 1022-1032
14. Haseneder R., Kratzer S., Kochs E., Eckle V.S., Zieglgansberger W., and Rammes G. Xenon reduces N-methyl-d-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated synaptic transmission in the amygdala. Anesthesiology 109 (2008) 998-1006
15. Hecker K., Baumert J.H., Horn N., and Rossaint R. Xenon, a modern anaesthesia gas. Minerva Anestesiol. 70 (2004) 255-260
16. Hudspith M.J. Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. Br. J. Anaesth. 78 (1997) 731-747
17. Kirson E.D., and Yaari Y. Synaptic NMDA receptors in developing mouse hippocampal neurones: functional properties and sensitivity to ifenprodil. J. Physiol. 497 Pt 2 (1996) 437-455
18. Kuner T., and Schoepfer R. Multiple structural elements determine subunit specificity of Mg2+ block in NMDA receptor channels. J. Neurosci. 16 (1996) 3549-3558
19. Laurie D.J., Bartke I., Schoepfer R., Naujoks K., and Seeburg P.H. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res. Mol. Brain Res. 51 (1997) 23-32
20. Leaver K.R., Allbutt H.N., Creber N.J., Kassiou M., and Henderson J.M. Neuroprotective effects of a selective N-methyl-d-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 35 (2008) 1388-1394
21. Liu L., Wong T.P., Pozza M.F., Lingenhoehl K., Wang Y., Sheng M., Auberson Y.P., and Wang Y.T. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304 (2004) 1021-1024
22. Lopez d.A., and Sah P. Development and subunit composition of synaptic NMDA receptors in the amygdala: NR2B synapses in the adult central amygdala. J. Neurosci. 23 (2003) 6876-6883
23. Lynch D.R., Shim S.S., Seifert K.M., Kurapathi S., Mutel V., Gallagher M.J., and Guttmann R.P. Pharmacological characterization of interactions of RO 25-6981 with the NR2B (epsilon2) subunit. Eur. J. Pharmacol. 416 (2001) 185-195
24. Ma D., Wilhelm S., Maze M., and Franks N.P. Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. Br. J. Anaesth. 89 (2002) 739-746
25. Malenka R.C., and Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 44 (2004) 5-21
26. McBain C.J., and Mayer M.L. N-methyl-d-aspartic acid receptor structure and function. Physiol. Rev. 74 (1994) 723-760
27. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., and Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256 (1992) 1217-1221
28. Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (1994) 529-540
29. Neyton J., and Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J. Neurosci. 26 (2006) 1331-1333
30. Ogata J., Shiraishi M., Namba T., Smothers C.T., Woodward J.J., and Harris R.A. Effects of anesthetics on mutant N-methyl-d-aspartate receptors expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 318 (2006) 434-443
31. Paoletti P., and Neyton J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7 (2007) 39-47
32. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. 429 (2001) 71-78
33. Parsons C.G., Danysz W., Hesselink M., Hartmann S., Lorenz B., Wollenburg C., and Quack G. Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments. Amino. Acids 14 (1998) 207-216
34. Preckel B., Weber N.C., Sanders R.D., Maze M., and Schlack W. Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology 105 (2006) 187-197
35. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., and Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 401 (1999) 63-69
36. Thoresen M., Hobbs C.E., Wood T., Chakkarapani E., and Dingley J. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J. Cereb. Blood Flow Metab. (2009) 29, 707-714
37. Vicini S., Wang J.F., Li J.H., Zhu W.J., Wang Y.H., Luo J.H., Wolfe B.B., and Grayson D.R. Functional and pharmacological differences between recombinant N-methyl-d-aspartate receptors. J. Neurophysiol. 79 (1998) 555-566
38. Villmann C., and Becker C.M. On the hypes and falls in neuroprotection: targeting the NMDA receptor. Neuroscientist 13 (2007) 594-615
39. Weigt H.U., Georgieff M., Beyer C., Wachter U., and Fohr K.J. Xenon incorporated in a lipid emulsion inhibits NMDA receptor channels. Acta Anaesthesiol. Scand. 47 (2003) 1119-1124
40. Weigt H.U., Adolph O., Georgieff M., Georgieff E.M., and Fohr K.J. Evidence that xenon does not produce open channel blockade of the NMDA receptor. J. Neurophysiol. 99 (2008) 1983-1987
41. Wenzel A., Fritschy J.M., Mohler H., and Benke D. NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J. Neurochem. 68 (1997) 469-478
42. Wilhelm S., Ma D., Maze M., and Franks N.P. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 96 (2002) 1485-1491
43. Xiao C., Huang Y., Dong M., Hu J., Hou S., Castellino F.J., Prorok M., and Dai Q. NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins. Neuropeptides 42 (2008) 601-609
44. Yamakura T., and Harris R.A. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 93 (2000) 1095-1101